Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Barriers and enablers to penicillin allergy assessment and testing in the intensive care unit: A mixed-methods study.

Journal of critical care·2026
Same author

Intraoperative parathyroid hormone assay benefits surgery for primary hyperparathyroidism when preoperative localisation is negative or not performed.

Annals of the Royal College of Surgeons of England·2024
Same author

Implementation and evaluation of a SARI surveillance system in a tertiary hospital in Scotland in 2021/2022.

Public health·2024
Same author

Venous thromboembolism in multiple myeloma: Increasing evidence in support of direct oral anticoagulants.

British journal of haematology·2023
Same author

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.

Clinical lymphoma, myeloma & leukemia·2022
Same author

The Use of Caffeine for Apnoea Associated with Trisomy 13 and Trisomy 18.

Irish medical journal·2022

Related Experiment Video

Updated: Jul 11, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Open label tissue plasminogen activator for stroke: the Oregon experience.

R Egan, H L Lutsep, W M Clark

    Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
    |September 27, 2007
    PubMed
    Summary

    Community treatment with tissue plasminogen activator (t-PA) for acute stroke is feasible. Outcomes in patients receiving t-PA mirrored those from the NINDS trial, demonstrating its effectiveness in real-world settings.

    More Related Videos

    The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
    06:38

    The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

    Published on: December 19, 2025

    A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
    09:42

    A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

    Published on: June 4, 2021

    Related Experiment Videos

    Last Updated: Jul 11, 2026

    Prehospital Thrombolysis: A Manual from Berlin
    05:52

    Prehospital Thrombolysis: A Manual from Berlin

    Published on: November 26, 2013

    The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
    06:38

    The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

    Published on: December 19, 2025

    A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
    09:42

    A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

    Published on: June 4, 2021

    Area of Science:

    • Neurology
    • Cardiovascular Medicine
    • Emergency Medicine

    Background:

    • Tissue plasminogen activator (t-PA) is a primary treatment for acute stroke.
    • This study evaluated t-PA treatment outcomes in a community setting following its 1996 approval.
    • The Oregon Stroke Center network facilitated the study.

    Purpose of the Study:

    • To assess the feasibility and outcomes of community-based t-PA treatment for acute stroke.
    • To compare community treatment results with established clinical trial data.

    Main Methods:

    • Screened patients within a 6-hospital network for t-PA eligibility.
    • Assessed outcomes using the National Institutes of Health Stroke Scale (NIHSS) at baseline and 24 hours.
    • Evaluated 3-month outcomes with the Modified Rankin scale.

    Main Results:

    • 33 patients treated within 3 hours of symptom onset; most had anterior circulation or cardioembolic strokes.
    • NIHSS scores showed modest improvement at 24 hours post-t-PA (mean 14.7 from 16.6).
    • 36% achieved minimal/no deficits at 3 months; 9% experienced symptomatic intracranial hemorrhage, with a 6% fatality rate.

    Conclusions:

    • Community-based t-PA treatment for acute stroke is feasible.
    • Achieved recovery rates align with findings from the National Institute of Neurologic Disorders and Stroke (NINDS) trial.
    • Highlights the successful integration of t-PA therapy into community stroke care.